Signs, symptoms, grading, and management

Immune-mediated dermatologic adverse reactions

 Skin icon

Signs and symptoms of dermatologic adverse reactions may include new or worsening1,2

  • Rash
  • Itching
  • Skin blistering or peeling
  • Swollen lymph nodes
  • Painful sores or ulcers in mouth, nose, throat, or genital area
  • Fever or flu-like symptoms

Management considerations for immune-mediated dermatologic adverse reactions1,2

CONSIDERATIONS SUSPECTED SJS, TEN, OR DRESS Confirmed SJS, TEN, OR DRESS
Dose modification
with OPDIVO, OPDIVO + YERVOY, or OPDIVO Qvantig
Withhold treatment Permanently discontinue treatment
Management

Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes.

Administer 1 to 2 mg/kg/day prednisone or equivalent until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.

Follow-up Consider administration of other systemic immunosuppressants, including corticosteroid therapy, if clinically appropriate.

When OPDIVO is administered in combination with YERVOY, if OPDIVO is withheld or discontinued, YERVOY should also be withheld or discontinued.1

OPDIVO® (nivolumab) vial icon
Dosing Information

Find the appropriate dosing information for your patients in any approved regimen with OPDIVO or OPDIVO Qvantig.

OPDIVO® (nivolumab) dosing guide icon
Dosing Guide

A guide to dosing intravenous OPDIVO and subcutaneous injection OPDIVO Qvantig across indications.

Clipboard with patient info icon
Patient Monitoring Checklist

A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions associated with OPDIVO, YERVOY, and OPDIVO Qvantig. 

References:

  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. OPDIVO Qvantig [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.


1506-US-2500048 02/25